Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Nanobiotix S.A.NASDAQ: NBTX
Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025
Accumulated OCI remains negative
Q4 FY2025 Accumulated OCI was -€376.15M, compared with -€311.51M a year earlier.
Context
- Accumulated OCI amounted to 555.1% of total assets at the end of Q4 FY2025, up 93.1 pp from a year earlier.
- Accumulated OCI grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -20.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
EUR · from the balance sheet
- Latest · FY2025
- (376.15M) EUR
- Year-over-year change
- -20.7%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (376.15M) | -20.7% |
| FY2024 | 2024-12-31 | (311.51M) | -12.8% |
| FY2023 | 2023-12-31 | (276.07M) | -21.8% |
| FY2022 | 2022-12-31 | (226.58M) | -23.9% |
| FY2021 | 2021-12-31 | (182.82M) | — |
Accumulated OCI vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -20.7% is the 3rd highest of 9, against a peer median of -93.7%.
- Accumulated OCI amounts to 555.1% of total assets for NBTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $26.88M USD | +437.9% | +440.9% | 4.4% | |
| Mar 2026 | $107K USD | -84.4% | — | 0.0% | |
| Mar 2026 | $105.64K USD | +583.2% | -11.6% | 0.1% | |
| Mar 2026 | $11K USD | -97.9% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$31K USD | -181.8% | +540887.8% | 0.0% | |
| Mar 2026 | -$36K USD | -89.5% | — | 0.0% | |
| Mar 2026 | -$270K USD | -1488.2% | — | 0.1% | |
| Mar 2026 | -$380K USD | -139.0% | — | 0.1% | |
| Dec 2025 | -€376.15M EUR | -20.7% | — | 555.1% | |
| Peer median (excluding NBTX) | — | -93.7% | +440.9% | 0.0% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83.92M | 41.39M | 75.28M | 49.74M | 52.75M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.89M | 2.84M | 2.97M | 8.54M | 7.68M |
| Inventory | 0 | 2.98M | 200K | 0 | 0 |
| Other Current Assets | 3.04M | 2.17M | 6.33M | (1K) | 2K |
| Total Current Assets | 93.06M | 52.36M | 87.34M | 61.47M | 62.75M |
| Property, Plant & Equipment (Net) | 8.19M | 7.12M | 6.11M | 5.54M | 4.57M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4K | 1K | 8K | 7K | 10K |
| Long-term Investments | 98K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 421K | 291K | 443K | 406K | 434K |
| Total Non-current Assets | 8.71M | 7.41M | 6.56M | 5.95M | 5.01M |
| Total Assets | 101.77M | 59.77M | 93.9M | 67.42M | 67.76M |
| Account Payables | 5M | 4M | 6.7M | 4.48M | 6.58M |
| Short-term Debt | 7.08M | 3.6M | 3.82M | 3.66M | 3.1M |
| Tax Payables | 5.08M | 6.6M | 7.38M | 6.87M | 6.82M |
| Deferred Revenue | 16.77M | 16.57M | 18.23M | 18.16M | 36.22M |
| Other Current Liabilities | 5.39M | 7.41M | 760K | 8.27M | 430K |
| Total Current Liabilities | 36.85M | 37.94M | 49.87M | 58.94M | 57.51M |
| Long-term Debt | 32.42M | 44.04M | 41.66M | 43.01M | 89.12M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 318K | 270K | 325K | 28.21M | 3.73M |
| Total Non-current Liabilities | 38.13M | 48.88M | 45.87M | 74.19M | 94.74M |
| Total Liabilities | 74.98M | 86.81M | 95.74M | 133.12M | 152.24M |
| Common Stock | 1.05M | 1.05M | 1.41M | 1.42M | 1.45M |
| Retained Earnings | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Accumulated OCI | (182.82M) | (226.58M) | (276.07M) | (311.51M) | (376.15M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 26.79M | (27.05M) | (1.84M) | (65.7M) | (84.48M) |
| Total Debt | 46.02M | 53.17M | 50.57M | 50.9M | 95.32M |
| Net Debt | (37.9M) | 11.78M | (24.72M) | 1.17M | 42.57M |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.